Posts

Showing posts from November, 2018
Image
COTPA Mediated Nicotine Displacement Therapy as an Effective Means of Tobacco Control Authored by Vishal Rao In Indian early one in two men and one in five women use tobacco causing eight to nine lakh adult deaths a year [1,2]. Government of India enacted the ‘Cigarettes and Other Tobacco Products (Prohibition of Advertisement and Regulation of Trade and Commerce, Production, Supply and Distribution) Act, in 2003 (hereafter referred to as COTPA). The major provisions of COTPA include; Prohibition of smoking in public places; Prohibition of direct and indirect advertisement of tobacco products; Prohibition on sale of tobacco products to and by minors, and within 100 yards of educational institutions; and Display of pictorial health warnings on tobacco products [3]. However, after a decade of enactment the compliance remains sub-optimal [4]. There is dearth of literature on how COTPA is being implemented and how it could be improved [5]. This paper analyzes COT

New Cancer Therapies-Juniper Publishers

Image
Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology New Cancer Therapies Authored by Daniela Vazquez Capdepon Malignant neoplasms are the second cause of death in Argentina, according to official data from the Argentine Ministry of Health, 25% of annual deaths are due to cancer, although it has detected a reduction of approximately 10% mortality rate cancer over the last 15 years. This condition causes between 55 and 60,000 deaths annually in Argentina. Values between 1% and 2.5% of the adult population, with a strong increase as the population ages. The new systemic cancer therapies are the result of decades of investment in research and clinical.  The two-way interaction between the clinic and the lab opened a whole new outlook, with a growing universe of “new molecular targets” possible to be manipulated pharmacologically. The mechanisms of regulation of cell signaling, generation of neovasculature (angiogenesis), cell cycle control, am

Chemoradiation with Capecitabine and Mitomycin-C for Stage I-III Anal Squamous Cell Carcinoma-Juniper Publishers

Image
Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology Chemoradiation with Capecitabine and Mitomycin-C for Stage I-III Anal Squamous Cell Carcinoma Authored by Hagen Kennecke Carcinoma of the anal canal is relatively uncommon, yet incidence is on the rise. The accepted current standard regimen for patients with stage I-III squamous cell carcinoma (SCC) of the anal canal is radiotherapy (50.4 Gy) with concurrent infusional 5-fluorouracil (5-FU) (825 mg/m2 per oral bi-daily) administered on radiation days during weeks one and five and mytomycin C (MMC) (12 mg/m2) administered on week one. This study describes the efficacy and safety of substituting oral capecitabine (Cap) for the infusional 5-FU and compares the planned versus delivered therapy, and describes treatment-related patient toxicities and early outcomes in a population-based setting. To Read More. . PHP  in  Cancer Therapy & Oncology International Journal  in Juniper Publishers

How Long Should Be The Radiation Oncology Treatment for Cervical Cancer? -Juniper Publishers

Image
Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology How Long Should Be The Radiation Oncology Treatment for Cervical Cancer? Authored by Luis Moreno Sanchez Historically locally advanced cervical cancer was treated with teletherapy and a boost with brachytherapy. But in 1999 the treatment changed favorably, thus establishing the current management based on concurrent chemo-radiotherapy, thanks to the publication of some studies [1,2] that showed survival advantage of this disease with the addition of platinum-based chemotherapy and radiotherapy. To Read More.. PHP  in Cancer Therapy & Oncology International Journal  in Juniper Publishers

Can Dynamic Conformal arc be an Option in Epidermoid Cervical Cancer Treatment? - Juniper Publishers

Image
Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology Can Dynamic Conformal arc be an Option in Epidermoid Cervical Cancer Treatment? Authored by  Jacksson S Historically locally advanced cancer of the cervix has been treated with radiotherapy and brachytherapy and it was not until 1999 that the use of concurrent chemotherapy was formalized due to excellent results in terms of rate of overall and disease-free survival. Box technique in radiotherapy is the most widely known providing excellent results, with some variations as oblique fields, but greatly increasing irradiation potentially healthy tissue, leading to the higher proportion of own side effects of each treatment. Therefore present a radiant treatment planning mode Dynamic Conformal Arc for cervical carcinoma.Treatment with dynamic conformal arc achieves better conformation of tumor and area to be treated, avoiding unnecessary doses to organs at risk (OAR), compared to conventional four

BRCA1 and BRCA2 Mutations are they Related to Breast Cancer in a Sample of Tunisian Population?-Juniper Publishers

Image
Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology BRCA1 and BRCA2 Mutations are they Related to Breast Cancer in a Sample of Tunisian Population? Authored by Awatef Msolly Mutations in the BRCA1/BRCA2 genes account for varying proportions of breast cancer families studied, and demonstrate considerable variation in mutational spectra coincident with ethnic and geographical diversity. This work aimed to identify mutations in BRCA1 and BRCA2 genes to explore the existence of population-specific recurrent or founder mutations, in Tunisian breast cancer families. We have screened for germline mutations in seventeen Tunisian high-risk breast cancer patients using direct sequencing. Index patients, diagnosed before age 45, possessing a positive family history or bilateral breast cancer were asked for detailed information on family history of breast or any other cancer type in their families. One family out of 17 (6%) carried BRCA 1 mutations and